Stifel Lays Out The Bull Case For Intuitive Surgical
Stifel analyst Rick Wise released a note upgrading Intuitive Surgical (NASDAQ: ISRG) from Hold to Buy and assigned a price target of $600.
Wise believes that “the next leg of the ISRG story is starting to take shape” in response to the company’s recently released earnings report.
There are several factors that are leading to these beliefs: 1) Procedure volumes appear to be recovering, 2) New product launches, 3) Future product launches are coming, 4) Intuitive Surgical is expanding geographically, 5) Expansions in global sales and marketing organization.
While the second quarter appeared to be strong, Wise did denote that 2014 is a transition year with challenges still remaining. These include ongoing capital spending, uncertainties involving the product cycle and the benign gynecological surgical market.
Sales growth and earnings power is key to stock price appreciation. Wise speculates “over the next 3-5 years, ISRG sales can grow sustainably at a 10% or better pace, and that EPS can grow 15-20%.”
He believes that the stock is under-earning relative to the company’s normalized earning power. If the re-acceleration thesis proves correct, Wise expects the stock to have an above-average multiple and to reach its $600 price target.
Shares in the pre-market were trading up 12.71 percent at $442.00.
Latest Ratings for ISRG
|Oct 2016||Wells Fargo||Initiates Coverage On||Outperform|
|Aug 2016||Raymond James||Initiates Coverage on||Outperform|
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.